Biceltis Trastuzumab Injection

Biceltis Trastuzumab Injection Specification

Usage
Hospital

Origin of Medicine
India

Pacakaging (Quantity Per Box)
1 vial per box

Indication
HER2-overexpressing breast and gastric cancers

Expiration Date
24-36 months from manufacturing date

Molecular Formula
C6470H10012N1726O2013S42

Salt Composition
Trastuzumab

Medicine Type
Injection

Dosage
440 mg/vial

Dosage Form
Lyophilized Powder for Reconstitution

Storage
Dry Place

Appearance
Liquid

Grade
Pharma

CAS No
180288-69-1

Assay
98%

Route of Administration
Intravenous infusion

Reconstitution Requirement
Requires reconstitution with sterile Water for Injection

Preservative
No preservative

Adverse Reactions
Infusion reactions, cardiotoxicity, pulmonary toxicity

Container Type
Single-use glass vial

Product Registration No.
As per Indian drug regulations

Contraindication
Hypersensitivity to Trastuzumab

Brand Name
Biceltis

Prescription Status
Prescription Only (Rx)

Therapeutic Class
Monoclonal Antibody

Compatibility
Do not mix with other drugs

Stability after Reconstitution
Stable for 24 hours at 2C to 8C

Biceltis Trastuzumab Injection Trade Information

Minimum Order Quantity
100 Packs

Supply Ability
5000 Packs Per Month

Delivery Time
7 Days

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

About Biceltis Trastuzumab Injection

Biceltis Trastuzumab Injection contains the active ingredient trastuzumab, which is a monoclonal antibody used in the treatment of HER2-positive breast cancer and certain other HER2-positive cancers. It works by targeting and binding to the HER2 protein, which is overexpressed in HER2-positive cancers. This is typically administered intravenously (into a vein) under the supervision of a healthcare professional. By binding to HER2, trastuzumab inhibits the growth and proliferation of cancer cells and can also stimulate the immune system to attack cancer cells. Furthermore, you can avail the offer of Biceltis Trastuzumab Injection at very reasonable prices.

Specification

Form	Injection
Prescription/Non prescription	Prescription
Treatment	To treat breast cancer
Manufacturer	Emcure
Composition	Trastuzumab
Brand	Biceltis

Precision Therapy for Cancer Treatment

Biceltis Trastuzumab Injection stands at the forefront of precision medicine for HER2-overexpressing breast and gastric cancers. By targeting specific cancer cell receptors, Biceltis helps slow tumor growth, offering renewed hope to patients. Used under hospital supervision, it delivers focused treatment for better clinical outcomes.

Quality, Safety, and Stability You Can Trust

Each vial of Biceltis is manufactured in India adhering to strict pharmaceutical standards. Supplied as a single-use glass vial containing pure lyophilized powder, Biceltis maintains stability for up to 24 months and up to 24 hours after reconstitution when properly refrigerated. It guarantees both safety and efficacy for patient care.

FAQ's of Biceltis Trastuzumab Injection:

Q: How is Biceltis Trastuzumab Injection prepared and administered?

A: The lyophilized powder in the single-use vial must be reconstituted with sterile Water for Injection before use. After reconstitution, the solution is administered via intravenous infusion in a hospital setting by qualified healthcare professionals.

Q: What are the main indications for Biceltis Trastuzumab Injection?

A: Biceltis is indicated for the treatment of HER2-overexpressing breast and gastric cancers, providing targeted therapy as part of a prescribed oncology regimen.

Q: When should Biceltis not be used?

A: Biceltis is contraindicated in patients who have a known hypersensitivity to Trastuzumab or any of its components. Always inform your healthcare provider of any allergies before starting treatment.

Q: Where should Biceltis be stored after reconstitution?

A: Once reconstituted, Biceltis should be stored between 2C and 8C and remains stable for 24 hours. The unused portion must be discarded after this period.

Q: What is the process for reconstituting Biceltis Trastuzumab Injection?

A: To reconstitute, add sterile Water for Injection to the vial as per the instructions provided in the product leaflet. Gently swirl-do not shake-until fully dissolved. The resulting liquid is clear to slightly opalescent and ready for infusion.

Q: What are some possible adverse reactions associated with Biceltis?

A: Patients may experience infusion reactions, cardiotoxicity, or pulmonary toxicity. Immediate medical supervision is advised during administration and for observation after infusion.